• Synergistic Activity of Macrolides and Partners Against M. a

  2026-08-03

  This study systematically investigates the in vitro efficacy of clarithromycin, temafloxacin, and ethambutol—both alone and in combination—against diverse strains of Mycobacterium avium complex. The research demonstrates that strategic antibiotic combinations, especially those including clarithromycin, yield additive or synergistic effects, offering insights for optimizing antibacterial strategies in challenging intracellular infection models.

• MG-132: Unlocking Proteasome Inhibition for Apoptosis Assays

  2026-08-03

  MG-132 (Z-LLL-al) empowers researchers with precise modulation of the ubiquitin-proteasome system, enabling high-fidelity apoptosis and cell cycle arrest studies. This guide delivers actionable workflows, troubleshooting insights, and context from the latest ROS-driven ferroptosis research, enabling you to maximize experimental reproducibility and interpretability.

• MMP-2 Responsive Liposomes Enable Sequential PD-1/IDO Target

  2026-08-02

  A recent study introduces a dual-targeted, MMP-2 responsive liposomal system for the sequential delivery of a PD-1 pathway-blocking peptide and an IDO inhibitor, substantially improving T cell reactivation and antitumor efficacy in breast cancer models. This approach remodels the immunosuppressive tumor microenvironment, offering a highly adaptable platform for advanced combination immunotherapy.

• ICG001: Precision Modulation of Wnt/β-Catenin in Regenerativ

  2026-08-01

  Discover how ICG001, a leading Wnt/β-catenin pathway inhibitor, enables precise control over stem cell signaling and disease modeling. Explore advanced scientific insights and practical assay implications for regenerative medicine and cancer research.

• Dissecting In Vitro Drug Response Metrics in Cancer Research

  2026-07-31

  Schwartz’s dissertation introduces a rigorous comparison of relative and fractional viability metrics to clarify how in vitro studies distinguish between antiproliferative and cytotoxic drug effects. This work offers researchers a more nuanced understanding of drug action timing and proportions, informing both assay design and translational oncology research.

• Dinaciclib (SCH727965): Precision Tools for Cell Cycle and B

  2026-07-31

  Dinaciclib (SCH727965) delivers high-specificity inhibition across key CDKs, enabling researchers to dissect cell cycle regulation, apoptosis, and tissue boundary dynamics in cancer and developmental models. This article demystifies protocol setup, advanced experimental use-cases, and troubleshooting strategies, with actionable guidance rooted in cutting-edge reference studies and APExBIO's trusted supply.

• CHIR 99021 Trihydrochloride: Optimizing GSK-3 Inhibitor Work

  2026-07-30

  CHIR 99021 trihydrochloride empowers researchers to precisely modulate stem cell fate and glucose metabolism in advanced organoid and metabolic models. This article translates recent breakthroughs into actionable protocols, troubleshooting guidance, and practical assay design, with a special focus on balancing self-renewal and differentiation.

• FPH1 (BRD-6125): Optimizing Hepatocyte Proliferation Workflo

  2026-07-30

  FPH1 (BRD-6125) enables robust, donor-independent expansion of human hepatocytes while enhancing functional markers like albumin secretion and CYP3A4 activity. This article delivers actionable protocol enhancements, troubleshooting strategies, and a unique bridge to optogenetic gene therapy innovations.

• Direct BAK Activation by SJ572946: A New Apoptosis Probe

  2026-07-29

  Sekar et al. report the discovery of SJ572946, a small molecule that directly activates BAK to trigger apoptosis, distinct from traditional BH3-mimetic approaches. This proof-of-concept expands the toolkit for dissecting mitochondrial apoptosis and offers new strategies for cancer research.

• Neuromedin S (rat): Technical Guide for GPCR Signaling Resea

  2026-07-29

  Neuromedin S (rat) provides researchers with a chemically defined, endogenous peptide agonist tailored for activation of neuromedin U receptors in rat-derived GPCR/G protein signaling assays. It is designed to ensure reproducibility and specificity in studies of energy homeostasis and stress response, but should not be used for diagnostic, therapeutic, or cross-species applications.

• Nicotinamide Adenine Dinucleotide (NAD+): Assay Reliability

  2026-07-28

  This article delivers a scenario-driven, evidence-based guide for leveraging Nicotinamide Adenine Dinucleotide (NAD+) (SKU B1793) in metabolic, viability, and cytotoxicity assays. Readers will find practical solutions to common lab challenges, direct literature links, and actionable workflow guidance rooted in validated product properties. APExBIO’s NAD+ is contextualized for reproducibility, cost-efficiency, and sensitive detection in cell-based research.

• FPH1 (BRD-6125): Unlocking High-Fidelity Hepatocyte Expansio

  2026-07-28

  Discover how FPH1 (BRD-6125) redefines primary human hepatocyte expansion, enabling robust, functionally mature cultures for advanced research and translational applications. This article reveals unique mechanistic insights and strategic protocols for maximizing assay fidelity.

• 3-Deazaadenosine: Advancing Epitranscriptomic and Antiviral

  2026-07-27

  Discover how 3-Deazaadenosine, a potent S-adenosylhomocysteine hydrolase inhibitor, uniquely enables precise manipulation of m6A RNA methylation and supports cutting-edge preclinical antiviral research. This analysis provides practical guidance for leveraging its mechanistic specificity in advanced disease models.

• CTP Solution (100 mM): Enabling Next-Gen mRNA Therapeutics

  2026-07-27

  Explore how CTP Solution (100 mM) empowers high-precision mRNA synthesis and advanced RNA-based therapies. Uncover the biochemical rationale, workflow enhancements, and translational impacts that set this Cytidine-5'-triphosphate reagent apart.

• Local Abaloparatide Drives FAK-Dependent Alveolar Bone Augme

  2026-07-26

  This study demonstrates that intraoral delivery of abaloparatide, a parathyroid hormone-related protein analog, can enhance alveolar bone thickness in situ by activating FAK-mediated periosteal osteogenesis. The findings offer a targeted approach for craniofacial bone regeneration, with implications for both basic signaling research and translational dentistry.

11484 records 1/766 page Next 12345 下5页 Last page